Selank vs Semax: How the Two Russian Nootropic Research Compounds Compare

Selank and Semax are the two most-discussed Russian-developed nootropic research compounds. They’re often confused, often stacked, and often misrepresented as interchangeable. They aren’t. The two research compounds have different parent molecules, different mechanisms, and different research profiles. Here’s a side-by-side look at what the published literature actually establishes.

Different origins, different jobs

Both research compounds were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the late 20th century, but they were derived from entirely different parent molecules.

• Selank is a synthetic analogue of tuftsin, an endogenous immunomodulatory research compound. It was designed primarily as an anxiolytic.
• Semax is a synthetic fragment of ACTH (adrenocorticotropic hormone), specifically the 4–10 sequence. It was designed primarily as a neuroprotective and cognitive agent.

In plain terms: Selank was built to dampen anxiety; Semax was built to protect and stimulate the brain.

Mechanism: where each research compound acts

Selank

The research literature describes Selank as modulating the GABAergic system, increasing expression of BDNF, and influencing serotonergic and dopaminergic tone. Studies in animal models and a small number of Russian human trials report anxiolytic effects comparable to benzodiazepines — without the sedation, dependence, or cognitive blunting.

Semax

Semax is studied as a neuroprotective research compound that increases BDNF and NGF (nerve growth factor) expression, modulates the melanocortin system, and influences dopaminergic signalling. It has been used clinically in Russia for stroke recovery and is the subject of an ongoing body of research on cognition and attention.

Half-life and administration

Both research compounds have very short plasma half-lives but produce effects that outlast the molecule itself, suggesting downstream signalling cascades. Both are typically administered intranasally in the research context, which bypasses first-pass metabolism and provides direct access to cerebral circulation.

Where the published evidence is strongest

• Selank: anxiolytic effects, modulation of inflammatory cytokines, improved stress resilience in animal models. A small number of human anxiety trials exist, mostly Russian.
• Semax: neuroprotection in ischaemic stroke models, BDNF/NGF upregulation, attention and executive function in animal studies, and Russian clinical use as a stroke adjunct.

Neither research compound has the volume of Western Phase 3 trials that, say, tesamorelin does. Most of the literature is Russian, smaller-scale, and not yet replicated at scale in English-language journals.

Are they stacked together?

In the research literature and in anecdotal community reports, yes — Selank for anxiolytic tone, Semax for cognitive activation. The two mechanisms don’t obviously conflict, and a handful of studies have looked at combinations. But there is no large clinical trial of the stack, so any claim of synergy in humans is speculative.

Side-effect profile

Both research compounds are reported in the literature as well-tolerated at research doses. Selank is notable for the absence of the sedation and dependence that typically accompany benzodiazepine-class anxiolytics. Semax can produce mild, transient irritability in some subjects at higher doses, consistent with its activating profile.

How to think about the two

• Studying anxiety modulation, calm focus, stress resilience → Selank.
• Studying neuroprotection, cognitive activation, attention → Semax (when available).
• They are complementary, not interchangeable. Treating them as the same molecule is a common mistake in the community.

Bottom line

Selank and Semax are two of the most interesting nootropic research compounds in the literature, but they answer different research questions. Pick the research compound that matches the mechanism you’re studying — or run them in parallel and document the difference. Either way, treat the published Russian data as a starting point, not as definitive English-language clinical evidence.

Browse the AUSPEPS Selank research guide for deeper mechanism and dosing detail, or view the full research compound range.